Patents by Inventor Fanny Mochel

Fanny Mochel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES
    Publication number: 20220062254
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Application
    Filed: June 22, 2021
    Publication date: March 3, 2022
    Inventors: Frédéric DARIOS, Giovanni STEVANIN, Fanny MOCHEL, Julien BRANCHU, Maxime BOUTRY
  • Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
    Patent number: 11065238
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 20, 2021
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDES
    Inventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
  • ANAPLEROTIC THERAPY OF HUNTINGTON DISEASE AND OTHER POLYGLUTAMINE DISEASES
    Publication number: 20190365695
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: February 4, 2019
    Publication date: December 5, 2019
    Inventors: Alexandra DURR, Fanny MOCHEL
  • INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES
    Publication number: 20190350913
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Application
    Filed: November 3, 2017
    Publication date: November 21, 2019
    Inventors: Frédéric DARIOS, Giovanni STEVANIN, Fanny MOCHEL, Julien BRANCHU, Maxime BOUTRY
  • TRIHEPTANOIN FOR THE TREATMENT OF GLUCOSE TRANSPORT 1 DEFICIENCY
    Publication number: 20190290610
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Application
    Filed: October 23, 2018
    Publication date: September 26, 2019
    Inventors: Fanny MOCHEL, Raphael SCHIFFMANN
  • Anaplerotic therapy of huntington disease and other polyglutamine diseases
    Patent number: 10220014
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: March 5, 2019
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Durr, Fanny Mochel
  • Triheptanoin for the treatment of glucose transport 1 deficiency
    Patent number: 10111848
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 30, 2018
    Assignees: National Institute of Health and Medical Research, Baylor Research Institute
    Inventors: Fanny Mochel, Raphael Schiffmann
  • COMPOSITIONS AND METHODS FOR TREATMENT OF MOVEMENT DISORDERS
    Publication number: 20180147175
    Abstract: The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.
    Type: Application
    Filed: January 23, 2018
    Publication date: May 31, 2018
    Inventor: Fanny MOCHEL
  • ANAPLEROTIC THERAPY OF HUNTINGTON DISEASE AND OTHER POLYGLUTAMINE DISEASES
    Publication number: 20180021287
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine disease, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: June 30, 2017
    Publication date: January 25, 2018
    Inventors: Alexandra DURR, Fanny MOCHEL
  • Urinary triaosylceramide (Gb3) as a marker of cardiac disease
    Patent number: 9750732
    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: September 5, 2017
    Inventors: Raphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Forni
  • Anaplerotic therapy of huntington disease and other polyglutamine diseases
    Patent number: 9717705
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: August 1, 2017
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Alexandra Durr, Fanny Mochel
  • TRIHEPTANOIN FOR THE TREATMENT OF GLUCOSE TRANSPORT 1 DEFICIENCY
    Publication number: 20160374980
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 29, 2016
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Triheptanoin for the treatment of glucose transport 1 deficiency
    Patent number: 9468229
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: October 18, 2016
    Assignees: NATIONAL INSTITUTE OF HEALTH AND MEDICAL RESEARCH, BAYLOR RESEARCH INSTITUTE
    Inventors: Fanny Mochel, Raphael Schiffmann
  • COMPOSITIONS AND METHODS FOR TREATMENT OF MOVEMENT DISORDERS
    Publication number: 20160296491
    Abstract: The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.
    Type: Application
    Filed: April 7, 2016
    Publication date: October 13, 2016
    Inventor: Fanny MOCHEL
  • Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
    Publication number: 20150342939
    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
    Type: Application
    Filed: June 3, 2015
    Publication date: December 3, 2015
    Inventors: Raphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Fomi
  • Urinary triaosylceramide (GB3) as a marker of cardiac disease
    Patent number: 9066939
    Abstract: The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: June 30, 2015
    Assignee: Baylor Research Institute
    Inventors: Raphael Schiffmann, Fanny Mochel, Lawrence Sweetman, Sabrina Forni
  • Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases
    Publication number: 20140364498
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 11, 2014
    Inventors: Alexandra Durr, Fanny Mochel
  • TRIHEPTANOIN FOR THE TREATMENT OF GLUCOSE TRANSPORT 1 DEFICIENCY
    Publication number: 20140221482
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Application
    Filed: December 13, 2013
    Publication date: August 7, 2014
    Applicants: Baylor Research Institute at Dallas, National Institute of Health and Medical Research
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases
    Publication number: 20120165405
    Abstract: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.
    Type: Application
    Filed: December 30, 2011
    Publication date: June 28, 2012
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Dürr, Fanny Mochel
  • TRIHEPTANOIN DIET FOR ADULT POLYGLUCOSAN BODY DISEASE (APBD) TREATMENT
    Publication number: 20110306663
    Abstract: Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months was 1-2 g/kg/24 hrs. The present invention demonstrates, for the first time, the arrest of clinical deterioration with limited functional recovery in APBD with triheptanoin diet therapy.
    Type: Application
    Filed: June 13, 2011
    Publication date: December 15, 2011
    Applicant: Baylor Research Institute
    Inventors: Raphael Schiffmann, Fanny Mochel